Screener
Medtronic MDT Diabetes — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Medtronic’s 10-K, filed June 18, 2026.
- Filed
- Jun 18, 2026, 4:27 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-044354
| (in millions) | Worldwide / Fiscal Year / 2026 | Worldwide / Fiscal Year / 2025 | Worldwide / Fiscal Year / 2024 |
|---|---|---|---|
| Surgical & Endoscopy | 6,764 | 6,498 | 6,508 |
| Acute Care & Monitoring | 2,051 | 1,909 | 1,908 |
| Medical Surgical | 8,815 | 8,407 | 8,417 |
| Reportable segment net sales | 33,079 | 30,734 | 29,654 |
| Diabetes | 3,112 | 2,755 | 2,488 |
| Other operating segment(1) | 135 | 137 | 221 |
| Other adjustments(2) | 39 | (90) | — |
| Total net sales | $36,364 | $33,537 | $32,364 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Medtronic's diabetes — net sales?
- Medtronic (MDT) reported diabetes — net sales of $838M in Q1 2026.
- How has Medtronic's diabetes — net sales changed year-over-year?
- Medtronic's diabetes — net sales increased by 15.1% year-over-year, from $728M to $838M.
- What is the long-term trend for Medtronic's diabetes — net sales?
- Over 4 years (2022 to 2026), Medtronic's diabetes — net sales has grown at a 7.4% compound annual growth rate (CAGR), from $2.34B to $3.11B.
- What does diabetes — net sales mean?
- This represents the total revenue generated from the sale of diabetes-related medical devices and services, net of returns, allowances, and discounts. It is the primary indicator of market demand and the commercial success of the diabetes product portfolio. Investors use this to gauge the segment's growth trajectory and market share performance.
Ask your AI about Medtronic's diabetes — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude